Heparin-induced thrombocytopenia (HIT)
======================================

Epidemiology of HIT
-------------------

Heparin-induced thrombocytopenia (HIT) is a drug-induced antibody-mediated immunological reaction resulting in arterial and/or venous thrombus formation. It can have serious and life-threatening consequences if it is not identified immediately and managed accordingly.

HIT is significantly more common in patients treated with unfractionated heparin (UFH) than in those treated with low-molecular-weight heparins (LMWH) ([@b84-btt-2-481]; [@b54-btt-2-481]) ([Table 1](#t1-btt-2-481){ref-type="table"}).

The frequency of HIT ranges between 0.2% and 3.0%, depending on the study population, being more common in surgical than in medical patients ([@b84-btt-2-481]; [@b20-btt-2-481]; [@b68-btt-2-481]; [@b75-btt-2-481]). With an incidence rate of 0.3%--0.5%, HIT is relatively uncommon in the critical care setting ([@b73-btt-2-481]). The frequency of HIT in medical patients on thrombosis prophylaxis with UFH and LMWH is also considerably low, 0.51% and 0.084%, respectively ([@b8-btt-2-481]). HIT seems to be more common in acute hemodialysis. In a study on 154 consecutive patients newly treated with hemodialysis, HIT was suspected in 6 (3.9%) and the clinical diagnosis was confirmed in all but one patient ([@b86-btt-2-481]). In contrast, in a UK national survey among patients on long-term hemodialysis, the incidence rate of HIT was only 0.32% ([@b35-btt-2-481]). Although HIT is clearly less frequent in medical than in surgical patients, it is nevertheless associated with a similarly high rate of thromboembolic complications and high treatment costs ([@b20-btt-2-481]; [@b8-btt-2-481]).

The increasing use of LMWH in thrombosis prophylaxis and treatment has contributed to the reduction in the incidence of HIT. However, despite the introduction of newer anticoagulants in the clinical routine, UFH still remains the anticoagulant of choice in certain medical conditions, particularly during cardiovascular surgery involving cardiopulmonary bypass (CPB) and in a sizable proportion of critically ill patients, thus maintaining the specter of HIT.

Pathogenesis of HIT
-------------------

HIT typically occurs 5--10 days after starting on heparin treatment ([@b84-btt-2-481]). Exposure to heparin molecules leads to expression of antibodies of the immunoglobulin G (IgG) class that bind to the platelet factor 4-heparin complex. This complex interacts with endothelial cells and platelets, resulting in activation of the coagulation cascade and formation of thrombi ([@b82-btt-2-481]; [@b19-btt-2-481]; [@b22-btt-2-481]). Thromboembolic complications can affect both the arterial and venous system.

Diagnosis of HIT
----------------

The diagnosis of HIT is primarily based on the course of reduction in platelet count and/or the development of thromboembolic event during treatment with heparin ([@b83-btt-2-481]). One must be aware of the possibility of this syndrome in any patient receiving either UFH or LMWH, including heparin flush for vascular access devices and extracorporeal systems.

Meticulous history taking and scrutiny of the course of reduction in platelet count are important in the diagnosis of HIT. Before considering every thrombocytopenia as HIT, one should carefully consider other potential causes of thrombocytopenia depending on the clinical condition of the patient. Particularly sepsis, other drug-induced thrombocytopenias and pseudothrombocytopenia should be considered. Nevertheless, HIT should always be suspected and appropriate management immediately implemented unless it is conclusive that other causes of thrombocytopenia are most likely.

Suspecting HIT in critically ill patients presenting with thrombocytopenia while receiving UFH or LMWH may be difficult. Firstly, the rate of thrombocytopenia in this patient group is as high as 30%--50% ([@b77-btt-2-481]; [@b9-btt-2-481]). Secondly, critically ill patients often present with an overlap of clinical syndromes (eg, disseminated intravascular coagulation, bone marrow suppression, liver failure, drug toxicity). This complexity may pose a serious diagnostic dilemma regarding HIT. In any case, treatment with heparin must be stopped and nonheparin anticoagulation immediately started until HIT can be ruled out with certainty.

Laboratory diagnosis of HIT is based on the identification of platelet factor 4 antibodies and functional platelet agglutination tests. The identification of HIT antibodies alone without any considerable reduction in platelet count or thrombocytopenia or thrombosis should not be considered as HIT ([@b83-btt-2-481]; [@b38-btt-2-481]; [@b25-btt-2-481]). Most of the asymptomatic patients with HIT antibodies do not develop HIT and thus do not need any specific treatment. The sensitivity and specificity of functional tests may be variable, and this may be influenced by the laboratory expertise. In general, a negative laboratory finding does not necessarily rule out HIT ([@b83-btt-2-481]). A conclusive diagnosis of HIT may thus be illusive in a small number of patients.

Management of HIT
-----------------

The first step in the management of HIT is to immediately stop any solution containing heparin and start with a non-heparin anticoagulant. Stopping exposure to heparin alone is not enough in the management of HIT ([@b80-btt-2-481]). Thrombin generation and clot formation as a result of the hemostatic activation due to HIT antibodies continue for several days or weeks even if heparin is stopped ([@b24-btt-2-481]; [@b25-btt-2-481]; [@b2-btt-2-481]). Therefore, nonheparin anticoagulants that do not cross-react with HIT antibodies should be administered in order to inhibit thrombin or thrombin generation.

Drugs used to treat HIT act by either inhibiting coagulation factor Xa or thrombin. Currently, danaparoid, lepirudin, and argatroban are approved for treatment of HIT. Danaparoid is a glycosaminoglycuronan isolated from porcine intestinal mucosa with an anti-Xa : anti-IIa activity ratio greater than 22. Its predominant effect is thus neutralizing factor Xa, thereby inhibiting the formation of thrombin. Lepirudin is a recombinant hirudin (r-hirudin) that irreversibly binds to both the substrate binding and catalytic sites of thrombin. Bivalirudin, another r-hirudin but with a reversible direct thrombin inhibition, is approved by the Food and Drug Administration (FDA) for use in patients with, or at risk of, HIT undergoing percutaneous coronary intervention. Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine, and it reversibly binds to the active site of thrombin. This review focuses on lepirudin, which is one of the oldest nonheparin anticoagulants used in the management of HIT.

Lepirudin
=========

Historical background
---------------------

Hirudin is a naturally occurring anticoagulant produced by the salivary glands of the medicinal leech *Hirudo medicinalis*. For several centuries, the leech had been used for medicinal purposes, particularly for bloodletting. Historical data from Persia and India show that the leech was used for such purposes as early as about 100 BC.

In his in vitro studies, Haycraft could demonstrate for the first time in 1884 the presence of a substance with anticoagulant properties in the leech extract ([@b29-btt-2-481]). The first parenteral anticoagulant treatment with a commercial hirudin was reported in 1909 ([@b13-btt-2-481]). However, inadequate supplies have made it practically impossible for the drug to be used in clinical medicine. The introduction of heparin that could be produced in large quantities changed the focus of research, and hirudin was almost ignored for decades. However, the advent of genetic engineering has made large production of the compound possible, one of the products of this recombinant approach being lepirudin.

The approval of lepirudin for treatment of patients with HIT was based on two prospective studies, the Heparin-Associated Thrombocytopenia (HAT)-1 and HAT-2 trials, which compared its efficacy with a historical cohort ([@b24-btt-2-481], [@b27-btt-2-481]). A recent investigation, the HAT-3 trial, further underlined the efficacy of lepirudin in the management of HIT ([@b50-btt-2-481]).

Biochemistry
------------

Hirudin comprises structurally similar single-chain poly-peptides of 65 or 66 amino acids with a compact amino-terminal core containing 3 disulphide bonds and an extended carboxy terminal with a sulphated tyrosine residue ([@b11-btt-2-481]).

Lepirudin (\[Leu1, Thr2\]-63-desulfatohirudin) has a molecular weight of 6979 Da. It is derived from transfected yeast cells using recombinant technology. In contrast to the natural compound, it is homogenous, comprising 65 amino acids, lacks a sulphated tyrosine residue at position 63 (thus termed desulfatohirudin), and contains leucine instead of isoleucine residue at position 1. Lepirudin has a specific activity of approximately 16,000 antithrombin units/mg ([@b1-btt-2-481]).

Pharmacology of lepirudin
-------------------------

### Mechanism of action

Lepirudin is a direct and irreversible inhibitor of thrombin, which is a key serine protease in the hemostatic system. Thrombin is generated via activation of its zymogen, pro-thrombin, by the prothrombinase complex (factor Xa/factor Va). The amount and the velocity of thrombin generation are decisive in the development of a stable clot ([@b31-btt-2-481]).

Lepirudin forms a stable noncovalent stoichometric 1:1 complex with thrombin, thereby inhibiting its procoagulant effects. It binds both to the substrate binding and catalytic sites of thrombin. In contrast to heparin, lepirudin is a direct thrombin inhibitor and it inhibits not only free but also clot-bound thrombin ([@b85-btt-2-481]).

The effect of lepirudin on thrombin is well described using the thrombin generation assay. Under physiological conditions, a very small amount of thrombin is generated in the initiation phase of the coagulation process, which is then followed by the amplification and propagation phases, culminating in the formation of a large amount of thrombin ([@b32-btt-2-481]; [@b70-btt-2-481]). Lepirudin prolongs the lag phase during thrombin generation. In therapeutic doses of lepirudin, the amount of generated thrombin (area under the thrombin generation curve) may be normal ([Figure 1](#f1-btt-2-481){ref-type="fig"}). However, with increasing doses of lepirudin, thrombin generation can also be reduced ([@b65-btt-2-481]).

By inhibiting the thrombin-thrombomodulin-induced protein C activation, hirudins might theoretically have a procoagulant effect. However, there is no evidence for this assumption.

### Absorption and distribution

Lepirudin is rapidly distributed throughout the extracellular space after intravenous (iv) administration. Its volume of distribution ranges between 12.2 and 32.1 L ([@b1-btt-2-481]), so that the drug is confined to the extracellular compartment ([@b53-btt-2-481]; [@b55-btt-2-481]; [@b78-btt-2-481]). Lepirudin does not cross the blood-brain barrier ([@b51-btt-2-481]) and it is not detected in breast milk ([@b48-btt-2-481]).

The pharmacokinetic properties of lepirudin following an iv administration are well described by a two-compartment model ([@b53-btt-2-481]; [@b63-btt-2-481]; [@b1-btt-2-481]). The initial plasma half-life of the drug is about 10 minutes, after which it is distributed in the extracellular space. Its terminal half-life in young healthy volunteers is about 1.3 hours. The bioavailability of the drug is also almost 100% with subcutaneous (sc) administration, with peak plasma drug concentration achieved in 3--4 hours ([@b79-btt-2-481]; [@b72-btt-2-481]).

Maximum activated partial thromboplastin time (aPTT) is reached about 10 min after an iv bolus, 3--6 hours after a 6-hour continuous iv infusion, and 2--3 hours after sc administration ([@b21-btt-2-481]).

The pharmacokinetic profile of lepirudin remains unchanged during repeated administrations, thus drug accumulation is unlikely in healthy state ([@b63-btt-2-481]).

### Metabolism and elimination of lepirudin

The primary elimination route of lepirudin is renal, accounting for approximately 90% of its systemic clearance ([@b52-btt-2-481]). It is partially hydrolyzed into amino acids in the kidney. About 35% of lepirudin is excreted in the urine unchanged ([@b55-btt-2-481]; [@b62-btt-2-481]). The systemic clearance of lepirudin is proportional to the glomerular filtration rate ([@b6-btt-2-481]). Therefore, the half-life of the drug increases with deterioration of renal function ([@b62-btt-2-481], [@b61-btt-2-481]; [@b78-btt-2-481]). The systemic clearance of lepirudin in women is about 25% lower than in men, and it is 20% lower in elderly patients than in younger patients ([@b1-btt-2-481]). These facts should be taken into consideration during lepirudin dosage.

Dosing lepirudin
----------------

Renal function must be taken into consideration while deciding on the initial and maintenance dose of lepirudin. Firstly, renal function declines with age. Secondly, elderly patients are the largest group of candidates for cardiovascular and orthopedic surgery. Thirdly, renal function may deteriorate during critical illness. Fourthly, serum creatinine is dependent on muscle mass, which declines with age. Therefore, simply taking serum creatinine for renal function assessment rather than creatinine clearance may result in overdosing lepirudin.

The dosing recommendations of lepirudin for HIT are given in [Table 2](#t2-btt-2-481){ref-type="table"}.

Laboratory monitoring of the anticoagulant effect of lepirudin must be conducted 3--4 hours after starting treatment and 3--4 hours after every dose change. Monitoring twice daily seems prudent. If the therapeutic range is not achieved, the dose should be increased by 20%. In case of overdose, lepirudin infusion must be stopped for 2 hours and then restarted at 50% of the last dose. Frequent laboratory monitoring and corresponding dose adjustments are necessary in patients undergoing CPB procedures.

Monitoring the anticoagulant effect of lepirudin
------------------------------------------------

Several assays have been evaluated for monitoring treatment with lepirudin, including the global test activated partial thromboplastin time (aPTT), ecarin clotting time (ECT) and enzyme-linked immunosorbent (ELISA) techniques ([@b59-btt-2-481]; [@b28-btt-2-481]).

Due to its inhibitory effect on thrombin, lepirudin results in prolongation of both aPTT and prothrombin time (PT). The aPTT is generally the current method of choice for monitoring treatment with lepirudin in most situations. However, there are considerable inter-individual variations in aPTT among patients treated with lepirudin. Furthermore, there is no linear correlation between aPTT and lepirudin at plasma concentrations of lepirudin greater than 0.6 mg/L ([@b67-btt-2-481]; [@b56-btt-2-481]; [@b28-btt-2-481]). This may result in overlooking toxic doses and the danger of bleeding.

The ECT defines the prolongation of clotting time caused by thrombin inhibition alone ([@b60-btt-2-481]; [@b66-btt-2-481], [@b67-btt-2-481]; [@b43-btt-2-481]). Ecarin is a metalloprotease obtained from the snake venom of *Echis carinatus.* It cleaves prothrombin, thereby exclusively generating meizothrombin, which is biologically similar to thrombin. However, meizothrombin cleaves fibrinogen much more slowly than thrombin. Thus, when all of the lepirudin in a blood sample is bound to meizothrombin, thrombin is no longer inhibited, which in turn results in clot formation. ECT shows a linear correlation to wide ranges of plasma lepirudin concentrations. Moreover, the inter-individual variation is low and the assay is not affected by heparin or antifibrinolytics ([@b67-btt-2-481]; [@b59-btt-2-481]; [@b28-btt-2-481]). ECT is more suitable than aPTT to monitor the anticoagulant effect of lepirudin particularly when higher doses are used, such as in CPB surgery.

Despite the merits of ECT measurement, there is no controlled study that proved the superiority of ECT over aPTT in reducing bleeding risk.

Antagonizing the effects of lepirudin
-------------------------------------

There is no specific antidote against lepirudin or any of the other hirudin derivatives. This is a major issue in areas where high anticoagulant activity may be required, particularly in cardiovascular surgery with extracorporeal circulation. In an in vitro model, desmopressin was shown to at least partially antagonize the effect of hirudin ([@b36-btt-2-481]). Other animal studies have also reported the use of desmopressin in reversing the effect of hirudin ([@b7-btt-2-481]; [@b4-btt-2-481]). However, human studies are still lacking. There are case reports on the successful use of recombinant activated factor VII in lepirudin-induced bleeding ([@b30-btt-2-481]; [@b64-btt-2-481]).

Another means of coping with bleeding due to lepirudin can be extracorporeal elimination systems. Some low-flux and all high-flux dialysis membranes are permeable to r-hirudin and may thus help to lower toxic doses of the drug ([@b5-btt-2-481]). Other authors concluded that modified ultrafiltration may enhance the elimination of r-hirudin, but plasmapheresis seems to provide the most rapid and complete elimination of the drug ([@b44-btt-2-481]). However, such extracorporeal techniques are not always a practical option in emergency situations.

Clinical efficacy of lepirudin in patients with HIT
---------------------------------------------------

The efficacy of lepirudin in the management of patients with HIT has been proven in the prospective HAT trials ([@b24-btt-2-481], [@b27-btt-2-481]; [@b50-btt-2-481]). Clinical results of HIT treatment are shown in [Table 3](#t3-btt-2-481){ref-type="table"}. The results of these studies underscore that once HIT is suspected, treatment should never be delayed. Delay between diagnosis of HIT and start of treatment with an alternative anticoagulant accounted for 61% of the thromboembolic complications observed during the HAT-3 trial. Summarizing the data of all patients included in the HAT trials, lepirudin decreased the risk for thromboembolic complications by 92.9% ([@b50-btt-2-481]).

A postmarketing drug monitoring program (DMP) involving 1329 patients treated with lepirudin has also shown the safety and efficacy of the drug in routine clinical practice ([@b21-btt-2-481]). The overall mortality rate attributed to a new thrombosis was only 1.4%. These favorable findings are most probably due to increasing knowledge and experience of clinicians. Furthermore, in contrast to the HAT trials, in which lepirudin was started after the laboratory confirmation of HIT, treatment of HIT in the DMP series was started once HIT was suspected.

Lepirudin in special circumstances
----------------------------------

Due to the lack of adequate antidote, the use of lepirudin in disease states requiring extracorporeal systems has been a concern in critical care medicine and CPB surgery. However, observational studies in the last few years have demonstrated that this issue may be solved if appropriate monitoring strategy is implemented.

### Lepirudin in artificial renal support

There are no large studies available on the safety and efficacy of lepirudin in patients on artificial renal support. However, case reports and observational studies have shown that the drug can be safely used in this patient group ([@b61-btt-2-481]; [@b6-btt-2-481]; [@b17-btt-2-481]; [@b71-btt-2-481]; [@b18-btt-2-481]).

Due to the predominantly renal elimination of lepirudin, careful drug dosing and coagulation monitoring are necessary to avoid an overdose in patients with renal dysfunction. Elimination half-lives of up to 316 hours have been reported in dialysis patients ([@b62-btt-2-481]). [@b78-btt-2-481] reported hirudin half-life in dialysis patients of more than 30 times than that in healthy controls. Minor improvements in renal function can result in a shorter elimination half-life of lepirudin. Therefore, frequent dose adjustments may be necessary in patients with acute renal failure, whose renal function may improve during the course of treatment ([@b17-btt-2-481]).

The type of dialysis membrane may also affect the pharmacokinetics of lepirudin. While most of the low-flux dialysis membranes are not permeable to hirudin, high-flux membranes may contribute to the elimination of the drug ([@b5-btt-2-481]; [@b44-btt-2-481]).

Repeated exposures to lepirudin may lead to an increased incidence of hirudin antibodies, which may result in marked reduction in renal clearance of the drug (see below).

### Lepirudin in cardiovascular surgery

Anticoagulation in patients with HIT undergoing CPB surgery poses a special problem. There is a marked activation of the coagulation system due to exposure of circulating blood to artificial surfaces in the CPB pump, making high-dose anticoagulation mandatory. UFH remained in this situation the anticoagulant of choice, because monitoring is easy and rapid and an effective antidote is available.

The issue of adequate monitoring and the lack of an antidote are very important while using lepirudin during CPB. Target lepirudin concentrations during CPB are 3.5 to 4.0 μg/mL ([@b67-btt-2-481]). Due to theses high doses of lepirudin, aPTT is not sufficient for monitoring ([@b67-btt-2-481]; [@b28-btt-2-481]). On the other hand, the lack of an effective antidote implies that an optimal anticoagulant monitoring is crucial to minimize the risk of bleeding. The introduction of ECT has allowed monitoring of lepirudin in high-dose ranges ([@b66-btt-2-481], [@b67-btt-2-481]). During CPB surgery, lepirudin dose can be adjusted based on ECT results that can be rapidly obtained using whole blood supplemented with normal human plasma ([@b67-btt-2-481]). This supplementation is important because CPB-associated hemodilution results in hypoprothrombinemia. Reliable ECT data cannot be obtained if plasma prothrombin levels are below 70% of normal ([@b43-btt-2-481]; [@b47-btt-2-481]).

Observational studies on patients with HIT have shown that cardiovascular surgery can be safely performed with lepirudin if stringent coagulation monitoring is instituted ([@b67-btt-2-481]; [@b37-btt-2-481]; [@b42-btt-2-481]; [@b14-btt-2-481]; [@b49-btt-2-481]). In one prospective controlled study comparing lepirudin with heparin in routine CPB surgery, lepirudin was shown to provide effective anticoagulation, but induced a higher postoperative blood loss than heparin ([@b69-btt-2-481]).

### Lepirudin in pregnancy

The use of lepirudin in pregnancy is generally not recommended, because the drug crosses the placenta. In a rabbit model, fetal hirudin plasma concentration was 1/60 that of maternal concentration ([@b51-btt-2-481]). Reports on the use of lepirudin in pregnancy are rare ([@b33-btt-2-481]; [@b46-btt-2-481]). In general, danaparoid is favored, because it does not cross the placenta ([@b46-btt-2-481]; [@b21-btt-2-481]).

### Lepirudin in children

The incidence of HIT in the pediatric population is low ([@b39-btt-2-481]; [@b57-btt-2-481]; [@b3-btt-2-481]), hence experience with lepirudin in children is anecdotal ([@b10-btt-2-481]; [@b74-btt-2-481]; [@b58-btt-2-481]; [@b41-btt-2-481]). Lepirudin at an infusion rate of 0.1 mg/kg bodyweight/hour seems adequate if renal function is normal ([@b74-btt-2-481]; [@b40-btt-2-481]). Further dose adjustments should be made based on coagulation results.

Lepirudin versus other drugs approved for treatment of HIT
----------------------------------------------------------

Direct comparative investigations between the drugs used in the treatment of HIT are not existent. Therefore, statements on this issue must be interpreted with caution. Retrospective comparison on the efficacy of lepirudin and argatroban has shown better results with lepirudin than with argatroban ([@b21-btt-2-481]). However, due to differences in study design, it is difficult to make a conclusive statement ([@b81-btt-2-481]). In another retrospective study by [@b76-btt-2-481], effective anticoagulation was achieved in 77.8% of argatroban patients and 69.5% of lepirudin patients. Major bleeding was documented in 10.3% and 11.5% of patients with argatroban and lepirudin, respectively.

In a retrospective study comparing lepirudin with danaparoid, there was no significant difference in efficacy between the two drugs in HIT patients with thrombosis at baseline treated with therapeutic doses ([@b15-btt-2-481]).

Complications of lepirudin treatment
------------------------------------

### Bleeding

Bleeding is the most important and clinically relevant complication of treatment with lepirudin, with an incidence rate of 4%--19% ([@b50-btt-2-481]). The reasons for this wide range in the reported bleeding frequencies may be differences in the study population and in monitoring of treatment. In a post-marketing DMP, the incidence of major bleeding episodes in patients with HIT and thrombosis treated with lepirudin was 5.4%, which is significantly lower than that in the HAT trials ([@b21-btt-2-481]). This may be attributed to a greater awareness and experience of physicians in dosing and monitoring lepirudin.

Elderly patients, patients with renal dysfunction and those with multiple organ dysfunction syndrome may be at high risk of bleeding complication. The hemostatic system is disturbed in critically ill patients. Besides renal dysfunction, deterioration in liver function may result in deficiency in coagulation factors, which can contribute to an increasing bleeding risk during treatment with lepirudin.

A further cause of increased bleeding risk during lepirudin administration is the concomitant use of anti-platelet drugs such as acetylsalicylic acid or GPIIb/IIIa inhibitors or fibrinolytic drugs.

Another issue is that the dosing generally recommended for treatment might be too high for a number of patients, who are mainly critically ill patients with at least one organ dysfunction ([@b50-btt-2-481]).

### Antibody development

Antibody development against hirudins is common, and this can be induced by both iv therapeutic and sc prophylactic doses ([@b23-btt-2-481]). In one study, the incidence of antibodies against r-hirudin was 84% in iv treated patients and 50% in sc treated patients ([@b34-btt-2-481]). In another study on 196 patients with HIT treated with lepirudin ([@b12-btt-2-481]), 44% developed antihirudin antibodies of the IgG class, and development of these antibodies correlated with the duration of treatment. Antihirudin antibodies are frequent in patients treated with lepirudin for more than 5 days.

By binding to lepirudin, antihirudin antibodies alter the pharmacokinetics of the drug, resulting in its longer half-life. Because the drug is mainly eliminated via the kidney, formation of lepirudin-antibody complexes may, due to their size, impair renal elimination, which may lead to accumulation of the drug. This phenomenon may thus enhance the anticoagulant effect of lepirudin ([@b12-btt-2-481]). The volume of distribution of these complexes is also decreased, indicating that antibody-bound lepirudin is mainly distributed in the intravascular compartment ([@b45-btt-2-481]). Elimination of the drug using dialysis membranes is also hampered ([@b16-btt-2-481]). Therefore, close coagulation monitoring is important during lepirudin treatment in patients with antihirudin antibodies.

### Allergic reaction

Eczema, rash, hot flushes, fever, chills, urticaria, bronchospasm, angioedema, and injection-site reactions have been reported in conjunction with the administration of lepirudin. Severe anaphylactic reactions have ensued in rare cases in close temporal relationship with the administration of lepirudin. These reactions were observed within minutes of iv bolus lepirudin administration. The risk of anaphylaxis was estimated at 0.015% for first exposure and 0.16% for repeat exposure to lepirudin ([@b26-btt-2-481]). High titer antihirudin antibodies of the IgG class but not of the IgE class were found in lepirudin-associated anaphylaxis. Avoiding iv bolus administration, if possible, may reduce the risk of severe anaphylactic reactions.

Conclusion
==========

Lepirudin has been proved to be effective and safe in the management of HIT. The drug is predominantly eliminated through the kidney. Therefore, renal function is a major determinant during dose adjustments. Important adverse effects are bleeding and development of antihirudin antibodies. The risk of bleeding can be reduced with increasing knowledge of physicians in dose adjustments and by implementing appropriate laboratory monitoring. The development of antihirudin antibodies may necessitate dose adjustments, particularly if patients are to be treated with lepirudin for more than 5 days. Anaphylactic reactions are very rare, and these seem to be associated with iv bolus administration of the drug.

Monitoring of lepirudin treatment can be achieved by means of aPTT in most circumstances. However, the correlation between aPTT and lepirudin is low at higher plasma lepirudin concentrations, such as required in CPB surgery. In such circumstances, ECT seems to be a better means of drug monitoring than aPTT.

The lack of an antidote against lepirudin is still a concern in certain clinical situations, particularly during CPB surgery. Nevertheless, increasing knowledge of physicians on the pharmacology of the drug and proper drug monitoring can help to reduce the risk of bleeding.
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###### 

Meta-analysis of the risk of heparin-induced thrombocytopenia (HIT) during thrombosis prophylaxis with low-molecular-weight heparin (LMWH) versus unfractionated heparin (UFH) (after [@b54-btt-2-481])

               HIT                Thrombocytopenia
  ------------ ------------------ -------------------
  LMWH         1/1255 (0.1%)      152/3758 (4.0%)
  UFH          31/1223 (2.5%)     238/3529 (6.7%)
  Odds ratio   0.1 (0.03--0.33)   0.47 (0.22--1.02)

###### 

Dosing recommendation for lepirudin use (intravenous administration) for heparin-induced thrombocytopenia (HIT)

  Clinical condition                                       Bolus dose (mg/kg body weight)                                 Maintenance dose
  -------------------------------------------------------- -------------------------------------------------------------- -----------------------
  HIT with thrombosis                                      0.40                                                           0.15 mg/kg/h
  HIT without thrombosis                                   none                                                           0.10 mg/kg/h
  HIT with thrombosis and concomitant thrombolysis         0.20                                                           0.10 mg/kg/h
  thrombosis prophylaxis in patients with history of HIT   none                                                           0.10 mg/kg/h
  intermittent hemodialysis                                0.08--0.10 predialysis                                         none
  Continuous veno-venous hemofiltration                    none                                                           0.005 mg/kg/h
  cardiac bypass surgery                                   0.25 and 0.20 in the priming fluid of the heart-lung machine   adjusted based on ECT

Except in cardiac surgery, treatment is generally monitored using aPTT, with a target aPTT ratio of 1.5--2.5. In cardiac surgery, anticoagulant monitoring is carried out using ecarin clotting time (ECT), which should be \>2.5 μg/mL before and 3.5--4.5 μg/mL during the cardiopulmonary bypass.

Dose regimens are taken from the Heparin-Associated Thrombocytopenia (HAT) trials ([@b24-btt-2-481], [@b27-btt-2-481]; [@b50-btt-2-481]).

###### 

Clinical results of treatment of heparin-induced thrombocytopenia (HIT) with lepirudin (after [@b50-btt-2-481])

  Clinical condition         Before treatment   During treatment   After treatment
  -------------------------- ------------------ ------------------ -----------------
  death                      0                  4.4%               10.2%
  limb amputation            1.0%               4.9%               0
  new thromboembolic event   8.3%               4.4%               1.0%
  combination of events      8.8%               11.2%              9.8%
  major bleeding             0                  19.5%              0
